Bone Morphogenetic Proteins an Update and Review
https://doi.org/10.26538/tjnpr/v1i1.2
Keywords:
Bone Morphogenetic Proteins, non-union, bone regeneration, surgery, segmental bone defectsAbstract
The use of biological factors for bone regeneration has revolutionized the management of fracture repair and spinal fusion. Various biological factors, such as bone morphogenetic proteins (BMP), fibroblast growth factors (FGF), platelet-derived growth factor (PDGF), insulin like growth factors (IGFs) and LIM mineralization protein-1(LMP-1), have been investigated for application in bone regeneration and skeletal repair. Even though autologous bone graft remains the gold standard for most orthopaedic procedures, the procedure suffers from significant disadvantages and hence different and novel approaches are being sought to achieve effective bone regeneration. Bone Morphogenetic proteins (BMPs) as a viable substitute to autologous bone graft have been the subject of intense research in the last few decades and have followed a long and iterative process to provide a burden of proof for clinical use at present time. In this review the focus is on growth and differentiation factors, specifically the bone morphogenetic proteins, which are of major experimental interest, the aim being the clinical use and acceptance of BMPs in the healing of large segmental bone defects.
References
Goldberg VM & Stevenson S. Natural history of autografts and allografts. Clin Orthop 1987; 225:7– 16.
Bauer TW & Muschler GF. Bone graft materials: an overview of the basic science. Clin Orthop Relat Res 2000; 371:10-27.
Friedlander GE. Current concepts review. Bone grafts. J. Bone Joint Surg 1987; 69:786–790.
Johnson AL & Stein LE. Morphologic comparison of healing patterns in ethylene oxide-sterilized cortical allografts and untreated cortical autografts in the dog. Am J Vet Res 1988; 49:101–105.
Gross TP, Jinnah RH, Clarke HJ & Cox QGN. The biology of bone grafting. Orthopaedics 1991; 14:563–568.
Kienapfel H, Sumner DR, Turner TM, Urban RM and Galante JO. Efficacy of autograft and freeze-dried allograft to enhance fixation of porous coated implants in the presence of interface gaps. J Orthop Res 1992; 10:423–433.
Virolainen P, Vuorio E & Aro HT. Gene expression at grafthost interfaces of cortical bone allografts and autografts. Clin Orthop 1993; 297:144–149.
Von Versen R. Experience in the processing of more than 50 000 bone grafts. In New trends in bone grafting, Acta Universitatis Tamperensis Series B 1992; 40:40-50.
Malinin TI (1992) Transplantation and banking of bone allografts. In New trends in bone grafting, Acta Universitatis Tamperensis Series B 1992; 40:187-190.
Tomford WW & Mankin HJ. Bone banking. Update on methods and materials. Orthop Clin North Am 1999; 30:565–570.
Friedlaender GE. Immune responses to osteochondral allografts. Current knowledge and future directions. Clin Orthop 1983; 174:58–68.
Pelker RR, Friedlaender GE, Markham TE, Panjabi MM & Moen CJ. Effects of freezing and freeze-drying on the biomechanical properties of rat bone. J Orthop Res 1984; 1:405–411.
Wolfe MW & Cook SD. Use of osteoinductive implants in the treatment of bone defects. Med Prog Tech 1994; 20:155–168.
Garbuz DS, Masri BA & Czitrom AA. Biology of allografting. Orthop Clin North Am 1998; 29:199–204.
Block JE & Poser J. Does Xenogeneic demineralized bone matrix have clinical utility as a bone graft substitute? Medical Hypotheses 1995; 45:27–32.
Salama R & Weissman SL.The clinical use of combined xenografts of bone and autologous red marrow. J Bone Joint Surg 1978; 60:111–115.
Salama R. Xenogenic bone grafting in humans. Clin Orthop 1983; 174:113–121.
Mehlisch DR, Taylor TD, Leibold DG, Hiatt R, Waite DE, Waite PD, Laskin DM & Smith ST. Collagen/hydroxyapatite implant for augmenting deficient alveolar ridges. J Oral Maxillofac Surg 1988; 44:839-846
Hashizume H, Tamaki T, Oura H & Minamide M. Changes in the extracellular matrix on the surface of sintered bovine bone implanted in the femur of a rabbit: An immunohistochemical study. J Orthop Sci 1998; 3:42–53.
Young C, Sandstedt P & Skoglund A. A comparative study of an organic xenogeneic bone and autogenous bone implants for bone regeneration in rabbits. Int J Oral Maxillofac Implants 1999; 14:72–76.
Urist MR. Bone: Formation by autoinduction. Science 1965; 150:893–899. 22. Oikarinen J & Korhonen LK. The bone inductive capacity of various bone transplanting materials used for treatment of experimental bone defects. Clin Orthop 1979 140:208–215.
Oikarinen J. Experimental spinal fusion with decalcified bone matrix and deep-frozen allogeneic bone in rabbits. Clin Orthop 1982; 162:210–218.
Einhorn TA, Lane JM, Burstein AH, Kopman CR & Vigorita VJ. The healing of segmental bone defects by demineralized bone matrix. J Bone Joint Surg 1984 66:274–279.
Lindholm TC, Lindholm TS, Alitalia I & Urist MR. Bovine morphogenetic protein (bBMP) induced repair of skull trephine defects in sheep. Clin Orthop 1988; 227:265–268.
Guizzardi S, Di Silvestre M, Scandroglio R, Ruggeri A & Savini R. Implants of heterologous demineralized bone matrix for induction of posterior spinal fusion in rats. Spine 1992; 17:701–707.
Hopp SG, Dahners LE & Gilbert JA. A study of the mechanical strength of long bone defects treated with various bone autograft substitutes: an experimental investigation in the rabbit. J Orthop Res 1989; 7:579–584.
Schwarz N, Schlag G, Thurnher M, Eschberger J, Dinges HP & Reddi H. Fresh autogeneic, frozen allogeneic, and decalcified allogeneic bone grafts in dogs. J Bone Joint Surg 1991; 73:787–790.
Russell JL & Block JE. Clinical utility of demineralized bone matrix for osseous defects, arthrodesis, and reconstruction: impact of processing techniques and study methodology. Orthopedics 1999; 22:524–531.
Wilkins RM, Kelly CM & Giusti DE. Bioassayed demineralized bone matrix and calcium sulfate: use in one-grafting procedures. Ann Chir Gynaecol 1999; 88:180–185.
Bucholz RW, Carlton A & Holmes RE. Hydroxyapatite and tricalcium phosphate bone graft substitutes. Orthop Clin North Am 1987; 18:323–334.
Elsinger E & Leal L. Coralline hydroxyapatite bone graft substitutes. J Foot Ankle Surg 1995; 35:396–399.
Guillemin G, Patat JL, Fournie J & Chetail M. The use of coral as a bone graft substitute. J Biomed Mat Res 1987; 21:557–567.
Heise U, Osborn JF & Duwe F. Hydroxyapatite ceramic as a bone substitute. Int Orthop 1990; 14:329–338.
Peltola M. Bioactive glass in frontal sinus and calvarial bone defect obliteration. Experimental and Clinical Studies. Thesis, Annales Universitatis Turkuensis 1990; 435-440..
Huggins C. The formation of bone under the influence of epithelium of the urinary tract. Arch Surg 1931; 22:377–408.
Reddi A. Bone Morphogenetic proteins: From basic science to clinical applications. JBJS 2001; 830:1-6.
Levander G. On the formation of new bone in bone transplantation Acta Chir Scand 1934; 74:425–436.
Spemann H. Embryonic development and induction. Yale University press 1938; 1035-1038;
Urist MR & Iwata H. A solubilized and insolubilized bone morphogenetic protein. Proc Natl Acad Sci USA 1979; 76:1828–1832.
Huggins CB. The formation of bone under the influence of epithelium of the urinary tract, Arch Surg 1931; 22:377-408.
Ripamonti U, Ma SS, van de Heever B & Reddi AH. Osteogenin, a bone morphogenetic protein, adsorbed on porous hydroxyapatite substrata, induced rapid bone differentation in calvarial defects of adult primates. Plast Reconstr Surg 1992; 90:382–393.
Wozney JM. Bone morphogenetic proteins and their gene expression Cellular and molecular biology, M. Noda, Editor. Academic press: San Diego. 1993; 131-167.
Vukicevic S, Latin V, & Chen P. Localization of osteogenic protein-1 (bone morphogenetic protein-7) during human embryonic development: high affinity binding to basement membranes. Biochemical and Biophysical Research Communications, 1994; 198:693-700.
Wozney JM. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 1992; 32:160–167.
Bruder SP & Fox BS. Tissue engineering of bone. Cell based strategies. Clin Orthop 1999; 367:68–83.
Takagi K & Urist MR. The role of bone marrow in bone morphogenetic protein-induced repair of femoral massive
diaphyseal defects. Clin Orthop 1982; 171:224–231.
Niederwanger M & Urist MR. Demineralized bone matrix supplied by bone banks for a carrier of recombinant human bone morphogenetic protein (rhBMP-2): a substitute for autogeneic bone grafts. J Oral Implantol 1996; 22:210–215.
Arnaud E, De Pollak C, Meunier A, Sedel L, Damien C & Petite H. Osteogenesis with oral is increased by BMP and BMC in a rat cranioplasty. Biomaterials 1999; 20:1909–1918.
Lane JM, Yasko AW, Tomin E, Cole BJ, Waller S, Browne M, Turek T & Gross J. Bone marrow and recombinant human bone morphogenetic protein-2 in osseous repair. Clin Orthop 19991; 361:216–227.
Noshi T, Yoshikawa T, Ikeuchi M, Dohi Y, Ohgushi H, Horiuchi K, Sugimura M, Ichijama K & Yonemasu K.
Enhancement of the in vivo osteogenic potential of marrow/hydroxyapatite composites by bovine bone
morphogenetic protein. J Biomed Mater Res 2000; 52:621–630.
Lacroix, P. "Recent investigation on the growth of bone". Nature 1945; 156:576.
Urist MR & Strates BS. Bone morphogenetic protein. J Dent Res 1971; 50:1392–1406.
Reddi, A. H. & Huggins, C. "Biochemical Sequences in the Transformation of Normal Fibroblasts in Adolescent Rat". PNAS 1972; 69:1601–1605.
Sampath TK & Reddi AH. Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentation. Proc Natl Acad Sci USA 1981; 78:7599–7603.
Sampath TK, Muthukumaran N & Reddi A H. "Isolation of Osteogenin, an Extracellular Matrix-Associated BoneInductive Protein, by Heparin Affinity Chromatography".PNAS 1987; 84:7109–7113.
Luyten FP, Cunninghan NS, Ma S, Muthukumaran N, Hammonds RG, Nevins WB, Woods WI & Reddi AH. "Purification and Partial Amino Acid Sequence of Osteogenin, a Protein Initiating Bone Differentiation". J Biol Chem 1989; 264:13377–13380.
Wozney JM. The bone morphogenetic protein family: multifunctional cellular regulators in the embryo and adult. Eur J Oral Sci 1998; 106:160-166.
Laurie SWS & Mulliken JB. Donor site morbidity after harvesting rib and illiac bone. Plast Reconstr Surg 1984;
:933-938.
Fernyhough JC & Weigel MC. Chronic donor site pain complicating bone graft harvesting from posterior illiac crest for spinal fusion. Spine 1992; 17:1474-1480.
Banwart JC & Hassanein RS. Iliac crest bone graft harvest donor site morbidity: A statistical evaluation. Spine 1995; 20:1055-1060.
Arrington ED and Chambers HG. Complications of illiac crest bone graft harvesting. Clin Orthop 1996; 329:300-309.
Schnee CL & Weil RJ. Analysis of harvest morbidity and radiographic outcome using autograft for anterior cervical
fusion. Spine 1997; 22:2222-2227.
Sampath TK & Reddi AH. "Dissociative Extraction and Reconstitution of Bone Matrix Components Involved in Local Bone Differentiation". PNAS 1981; 78:7599–7603.
Wang ERV, Cordes P, Hewick R, Kriz M, Luxenberg D, Sibley B & Wozney JM. Purification and characterisation of other distinct bone inducing proteins. Proc Natl Acad Sci 1998; 85:9484-9488.
Celeste AJ, Iannazzi JA, Taylor RC, Hewick RM, Rosen V, Wang EA & Wozney JM. Identification of transforming growth factor β family members present in bone-inductive protein purified in bovine bone. Proc Natl Acad Sci USA 1990; 87:9843–9847.
Sampath T, Rashka K, Doctor J, Tucker R & Hoffman F. Drosophila TGF β superfamily proteins induced endochondral bone formation in mammals. Proc Natl Acad Sci 1993; 90:6004-6008.
Urist MR & Finerman G. Bone cell differentiation and growth factors. Science 1983; 220:680-686.
Uwagie-Ero EA, Kene ROC, Chilaka FC, Kadima KB, Awasum CA, Udegbunam RI, Nnaji, TO & Udegbunam SO. New bone formation induced by bovine bone morphogenetic protein extract. Asian Acad Res J 2014; 1: 472 – 480
Tsuda TMK, Yoshikawa H, Shimuzu N, Takaoka K. Establishment of an osteoinductive murine osteosarcoma clonal
cell line showing osteoblastic phenotypic traits. Bone 1989; 10:195-200.
Takoka KYH, Masuhara K, Sugamoto K, Tsuda T, Aoki Y, Ono Y & Sakamoto Y. Establishment of a cell line producing BMP from a human osteosarcoma. Clin Orthop 1989; 244:258-264.
Urist MR & Lietze A. A solubilized and insolubilized bone morphogenic protein. Proc Natl Acad Sci 1979; 76:1828-1832.
Bauer FUM.Human osteosarcoma derived soluble bone morphogenetic protein. Clin Orthop 1981; 154:291–295
Griffith D, Keck PC; Sampath TK; Rueger DC & Arlson WD. Three-dimensional structure of recombinant human osteogenic protein 1: Structural paradigm for the transforming growth factor β superfamily. Proc Natl Acad Sci USA 1996; 93:878-883.
Massague J. TGF -β signal transduction. Annu Rev Biochem 1998; 67:753-791.
Kingsley DM. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different
organisms. Genes Dev 1994; 8:133-146.
Demers C & Hamdy RC. Bone morphogenetic proteins. Science & Medicine 1999; 6:8-17.)
Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, & Wang EA. Novel regulators of bone formation: Molecular clones and activities. Science 1988; 242: 1528–1534.
Franceschi R. The developmental control of osteoblast specific gene expression: role of specific transcription factors and the extracellular matrix environment. Crit Rev Oral biol Med 1999; 10:40-57.
Nishida YKC, Eger W, Kuettner KE & Knudson W. Osteogenic protein 1 stimulates cell associated matrix assembly by normal human articular chondrocytes up regulation of hyaluronan synthase, CD 44, and aggrecan. Arthritis Rheum 2000; 43:206-214.
Nishida YKC, Eger W, Kuettner KE & Knudson W. Osteogenic Protein 1 promotes the synthesis and retention of extracellular matrix within bovine articular cartilage and chondrocyte cultures. Osteoarthritis Cartilage. 2000; 8:127-136.
Reddi A. Bone and cartilage differentiation. Curr opin genet dev 1994; 4:737-744.
Reddi A. Cartilage morphogenesis: role of bone and cartilage morphogenetic proteins, home box genes and extracellular matrix. Matrix Biol 1995; 14:599-606.
Reddi A. Fracture repair process: Initiation of fracture repair by bone morphogenetic proteins. Clin Orthop and related research. 1998; 355:66-72,
Reddi A. Morphogenetic messages are in extracellular matrix: biotechnology from bench to bedside. Biochem soc tras 2000, 28:345-349
Reddi A. Bone morphogenetic proteins and skeltal development: the kidney - bone connection. Pediatr Nephrol
, 14:598-601,
Hogan B. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Gees Dev 1996; 10:1580-1594.
Hogan B. Bone Morphogenetic proteins in development. Curr opin genet dev 1996; 6:432-438.
Sampath TRD. Structure, function and orthopedic applications of osteogenic protein -1. Complications in Orthopedics 1994; 9:101-107.
Sampath TK, Maliakal JC & Hauschka PV. Recombinant human osteogenic protein-1 (HOP-1) induces new bone
formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates steoblast
proliferation and differentiation in vitro. JBiol Chem 1992; 267: 20352-20362.
Wozney JM. Bone morphogenetic proteins. Prog Growth Fact Res 1993; 1:267–80.
Nevins M, Camelo M & Nevins ML. Periodontal regeneration in humans using recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and allogenic bone. J Periodontol1989; 74:1282-1295.
Boyne PJ, Lilly LC & Marx RE. De novo bone induction by recombinant human bone morphogenetic protein -2 (rhBMP-2) in maxillary sinus floor augmentation. J Oral Maxillofac Surg 2005; 63:1693-1699.
Fiorellini JP, Howell TH & Cochran D. Randomized study evaluating recombinant human bone morphogenetic protein -2 for extraction socket augmentation. J Periodontol 2005; 76: 605-609.
Jones AL, Bucholz RW & Bosse MJ. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects: A randomized, controlled trial. J Bone Joint Surg Am 2006; 88:1431-1443.
Dickinson BP, Ashley RK & Wasson KL. Reduced morbidity and improved healing with bone morphogenic protein -2 in older patients with alveolar cleft defects. Plast Reconstr Surg2008; 121:209-217.
Herford AS & Boyne PJ. Reconstruction of mandibular continuity defects with bone morphogenetic protein -2 (rhBMP-2). J Oral Maxillofac Surg 2008; 66: 616-626.
O'Shaughnessy BA, Kuklo TR & Ondra SL. Surgical treatment of vertebral osteomyelitis with recombinant human bone morphogenetic protein -2. Spine 2008; 237:3313–3323.
Chen D, Harris MA & Rossini G. Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell
differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif Tissue Int 1997; 60:283.
Siddappa R, Martens A & Doorn J. cAMP/PKA pathway activation in human mesenchymal stem cells in vitro results in robust bone formation in vivo. Proc Natl Acad Sci USA 2008; 105:7281-7288.
Tang TT, Xu XL & Dai KR. Ectopic bone formation of human bone morphogenetic protein -2 gene transfected goat bone marrow-derived mesenchymal stem cells in nude mice. Chin J Traumatol 2005; 8:3-9.
Minamide A, Yoshida M & Kawakami M. The use of cultured bone marrow cells in type I collagen gel and porous
hydroxyapatite for posterolateral lumbar spine fusion. Spine2005; 30:1134-1140.
Martin GJ, Boden SD, Marone MA & Moskovitz PA. Posterolateral intertransverse process spinal arthrodesis with
rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier and safety. J Spinal Disord 1999;
:179–86.
Govender S, Csimma C & Genant HK. Recombinant human bone morphogenetic protein -2 for treatment of open tibial fractures: A prospective, controlled, randomized study of four hundred and fifty patients, J Bone Joint Surg Am 2002; 84: 2123-2127.
Ashley RLJ. Safety profile for the clinical use of bone morphogenetic protein in the spine. Spine 2002; 28:372-377.
Wang L, Park P, La Marca F, Than KD, Lin C, BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation, Journal of Cancer Research and Clinical Oncology 2015; 141:1013-1018.
Orui HI & Ogino T. Effects of Bone morphogenetic protein 2 on human tumor cell growth and differentiation: a preliminary report. J Orthop Sci 2002; 5:600-604.
Poynton AR. Safety profile for clinical use of bone morphogenetic protein in the spine. Spine 2002; 27: 40-48.
Burkus JK, Dorchak JD & Sanders DL. Radiographic assessment of interbody fusion using recombinant human bone morphogenetic protein type 2. Spine 2003; 28: 372-377.
Paramore CG & Rauzzino J. The safety of OP-1 for lumbar fusion with decompression: A cnaine study. Neurosurgery 1999; 44:1151-1156.
Boden SD. Bioactive factors for bone tissue engineering. Clin Orthop 1999; 367:84–94.
Pacicca DM, Patel N & Lee C. Expression of angiogenic factors during distraction osteogenesis. Bone 2003; 33:889-898.
Sakou T. Bone morphogenetic proteins: from basic studies to clinical approaches. Bone, 1998; 22:591-603.
Groppe J, Greenwald J & Wiater E. Structural basis of BMP signalling inhibition by the cystine knot protein noggin. Nature2002; 420:636-642.
Bahamonde ME & Lyons KM. BMP3: to be or not to be a BMP. Journal of Bone and Joint Surgery 2001; 83:56-62.
Zhao Y, Zhang J, Wang X, Chen B, Xiao Z, Shi C, Wei Z, Hou X, Wang Q. & Dai J. The osteogenic effect of bone
morphogenetic protein -2 on the collagen scaffold conjugated with antibodies. Journal of Controlled Release 2010; 141:30-37.
Wozney JM & Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop 1998; 346:26–37.
Lindholm TS & Gao TJ. Functional carriers for bone morphogenetic proteins. Ann Chir Gynaecol 1993; 82:3–12.
Ripamonti U. Delivery systems for bone morphogenetic proteins. A summary of experimental studies in primate models. Ann Chir Gynaecol 1993; 82:13–25.
De Groot J. Carriers that concentrate native bone morphogenetic protein in vivo. Tissue Eng 1998; 4:337–341.
Winn SR, Uludag H & Hollinger JO. Carrier systems for bone morphogenetic proteins. Clin Orthop 1999; 367:95–106.
Lane JM, Tomin E & Boström MP. Biosynthetic bone grafting. Clin Orthop 1999; 367:107– 117.
Aldinger G, Herr G, Kusswetter W, Reis HJ, Thielemann FV & Holz U. Bone morphogenetic protein: A review. Int Orthop 1991; 15:169–177.
Cook SD & Tan EH. In vivo evaluation of recombinant human osteogenic protein (rh OP1) implants as bone graft substitute for spinal fusion. Spine 1994; 19:1655-1663.
Hollinger JO & Leong K. Poly(alpha-hydroxy acids):carriers for bone morphogenetic proteins. Biomaterials 1996; 17:187–194.
Uwagie-Ero EA, Awasum CA, Kene ROC, Chilaka FC. Use of native bovine BMP in the treatment of large segmental tibia defects in goats. J. Veterinar Sci 2016; Techno 7:329-336.
Tiainen J, Knuutila K, Veiranto M, Suokas E, Tormala P, Kaarela O, Länsman S & Ashammakhi N. Pull-out strength of multifunctional bioabsorbable ciprofloxacin-releasing polylactide-polyglycolide 80/20 tacks: an experimental study
allograft cranial bone. J Craniofac Surg 2009; 20:58-61.
Wang EA, Rosen V, D′Alessandro JS, Baunduy M, Cordes P, Harada T, Israel DI, Hewick RM, Kerns KM, LaPan P,
Luxenberg DP, McQuaid D, Moutsatsos IK, Nove J & Wozney JM, Recombinant human bone morphogenetic protein induces bone formation Proc Natl Acad Sci 1999; 87:2220-2224.
Langer R. & Vacanti JP. Tissue engineering. Science 1993; 260:920–926.
Takaoka K, Nakahara H, Yoshikawa H, Masuhara K, Tsuda T & Ono K Ectopic bone induction on and in porous
hydroxyapatite combined with collagen and bone morphogenetic protein. Clin Orthop 1988; 234:250–254.
Damien CJ, Parsons JR, Benedict JJ & Weisman DS. Investigation of a hydroxyapatite and calcium sulfate composite supplemented with an osteoinductive factor. J Biomed Mater Res 1990; 24:639–654.
Horisaka Y, Okamoto Y, Matsumoto N, Yoshimura Y, Kawada J, Yamashita K and Takagi T. Subperiosteal implantation of bone morphogenetic protein adsorbed to hydroxyapatite. Clin Orthop 1991; 268:303–312.
Ono I, Gunji H, Kaneko F, Saito T & Kuboki Y. Efficacy of hydroxyapatite ceramic as a carrier for recombinant human bone morphogenetic protein. J Craniofac Surg 1995; 6:238–244.
Asahina I, Watanabe M, Sakurai N, Mori M & Enomoto S. Repair of bone defect in primate mandible usinf a bone
morphogenetic protein (BMP)-hydroxyapatite-collagen composite. J Med Dent Sci 1997; 44:63–70.
Koempel JA, Patt BS, O'Grady K, Wozney JM & Toriumi DM. The effect of recombinant human bone orphogenetic protein-2 on the integration of porous hydroxyapatite implants with bone. J Biomed Mater Res 1998; 41:359–363.
Boden SD, Martin GJ, Morone MA, Ugbo JL & Moskovitz PA. Posterolateral lumbar intertransverse processus spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine 1999; 24:1179–1185.
Yoshida K, Bessho K, Fujimura K, Konishi Y, Kusumoto K, Ogawa Y & Iizuka T. Enhancement by recombinant human bone morphogenetic protein-2 of bone formation by means of porous hydroxyapatite in mandibular bone defects. J Dent Res 1999; 78:1505–1510.
Nohe A, Keating E, Knaus P & Petersen NO. Signal transduction of bone morphogenetic protein receptors. Cell
Signal 2004; 16:291-299.
Magan A & Ripamonti U. Geometry of porous hydroxyapatite implants influences osteogenesis in baboons. J Craniofac Surg 1996; 1:71–78.
Kuboki Y, Takita H, Kobayashi D, Tsuruga E, Inoue M, Murata M, Nagai N, Dohi Y & Ohgushi H. BMP-induced osteogenesis on the surface of hydroxyapatite with geometrically feasible and no feasible structures: topology of osteogenesis. J Biomed Mater Res 1998; 39:190–199.
Gao TJ, Lindholm TS, Kommonen B, Ragni P, Paronzini A, Lindholm TC, Jalovaara P & Urist MR. The use of coral
composite implant containing bone morphogenetic protein to repair a segmental tibial defect in sheep. Int Orthop 1997; 21:194–200.
Sciadini MF, Dawson JM & Johnson KD. Evaluation of bovinederived bone protein with a natural coral carrier as a bone-graft substitute in a canine segmental defect model. J Orthop Res 1997; 15:844–857.
http://www.infusebonegraft.com/hospital-administrators/fdaapproval-pathways/index.htm
Nilsson OS, Urist MR, Dawson EG, Schmalzried TP & Finerman GAM Bone repair induced by morphogenetic protein in ulnar defects in dogs. J Bone Joint Surg 1986; 68:635–642.
Delloye C, Verhelpen M, d`Hemricourt J, Govaerts B & Bourgois R. Morphometric & physical investigations of
segmental cortical bone autografts and allografts in canine ulnar defects. Clin Orthop 1992; 282:273–292.
Cook SD, Baffels GC, Wolf MW, Sampath TK & Rueger DC. Recombinant human bone morphogenic protein-7 induces healing in a canine long-bone segmental defect model. Clin Orthop 1994; 301:302–312.
Uwagie-Ero EA, Awasum CA, Kadima, KB and Adeyanju JB. An evaluation of the effect of bone morphogenetic protein-2 in a hydroxyapatite carrier on the rate of cortical restoration of large bone defects using the dog ulna model. Sokoto Journal of Veterinary Sciences 2016; 14: 53-57.
Moore DC, Chapman MW & Manske D. The evaluation of a biphasic calcium phosphate ceramic for use in grafting long-bone diaphyseal defects. J Orthop Res 1987; 5:356–365.
Grundel RE, Chapman MW, Yee T & Moore DC. Autogeneic bone marrow and porous biphasic calcium phosphate ceramic for segmental bone defects in the canine ulna. Clin Orthop 1991; 266:244–258.
Johnson EE, Urist MR, Schmalzried TP Autogeneic cancellous bone grafts in extensive segmental ulnar defects in dogs. Effects of xenogeneic bovine bone morphogenetic protein without and with interposition of soft tissues and interruption of blood supply. Clinical Orthopaedics and Related Research, 1989; 243: 254-265.
Heckman JD, Ehler W, Brooks BP, Aufdemorte TB, Lohmann CH, Morgan T & Boyan BD. Bone morphogenetic protein but not transforming growth factor-β enhances bone formation in canine diaphyseal non-unions implanted with a biodegradable composite polymer. J Bone Joint Surg 1999; 81:1717–29.
Heckman JD, Ehler W, Brooks BP, Aufdemorte TB, Lohmann CH, Morgan T and Boyan BD. Bone morphogenetic protein but not transforming growth factor-β enhances bone formation in canine diaphyseal non-unions implanted with a biodegradable composite polymer. J Bone Joint Surg 1999; 81:1717–1729.
Johnson AL and Stein LE. Morphologic comparison of healing patterns in ethylene oxide-sterilized cortical allografts and untreated cortical autografts in the dog. Am J Vet Res 1988; 49:101-105.
Johnson EE, Urist MR & Schmalzried TP. Autogeneic cancellous bone grafts in extensive segmental ulnar defects in dogs. Effects of xenogeneic bovine bone morphogenetic protein without and with interposition of soft tissues and interruption of blood supply. Clinical Orthopaedics and Related Research, 1989; 243:254-265.
Enneking WF, Burchardt H, Puhl JJ & Pietrowski G. Physical and biological aspects in dog cortical-bone transplants. J Bone Joint Surg 1975; 57:237–252.
Burchardt H, Jones H, Glowczewskie F, Rudner C & Enneking WF. Freeze-dried allogeneic segmental cortical-bone grafts in dogs. J Bone Joint Surg 1978; 60:1082–1090.
Marcacci M, Kon E, Zaffagnini S, Giardino R, Rocca M, Corsi A, Benvenuti A, Bianco P, Quarto R, Martin I, Muraglia A & Cancedda R. Reconstruction of extensive long-bone defects in sheep using porous hydroxyapatite sponges. Calcif Tissue Int 1999; 64:83–90.
Zellin G & Linde A. Treatment of segmental defects in long bones using osteopromotive membranes and recombinant human bone morphogenetic protein-2. An experimental study in rabbits. Scand J Plast Reconstr Hand Surg 1997; 31:97–104.
Teixeira JO & Urist MR. Bone morphogenetic protein induced repair of compartmentalized segmental diaphyseal defects. Arch Orthop Trauma Surg 1998; 117:27–34.
Wheeler DL, Chamberland DL, Schmitt JM, Buck DC, Brekke JH, Hollinger JO, Joh SP & Suh KW. adiomorphometry and biomechanical assessment of recombinant human bone morphogenetic protein 2 and polymer in rabbit radius
osteotomy model. J Biomed Mater Res 1998; 43:365–373.
Nottbaert M, Lane JM, Burstein JA, Schneider R, Klein Ch, Sinn RS, Dowling CH, Cornell C & Catsimpoolas N. Omental angiogenic lipid fraction and bone repair, An experimental Study in the rat. J Orthop Res 1989; 157–169.
Ohura K, Hamanishi C, Tanaka S & Matsuda N. Healing of segmental bone defects in rats induced by a β-TCP-MCPM cement combined with rhBMP-2. J Biomed Mater Res 1999; 44:168– 175.
Reddi AH. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian orphogens. Cytokine and Growth Factor Reviews, 1997; 8:11-20.
Wang EA, Israel DI & Kelly S. Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors, 1993; 9:57-71.
Kirker-Head CA. Potential applications and delivery strategies for bone morphogenetic proteins. Advanced Drug Delivery Reviews, 2000; 43:65-92
Hofbauer LC & Heufelder AE. Updating the metalloprotease nomenclature: bone morphogenetic protein 1 identified as procollagen C proteinase. European Journal of Endocrinology, 1996; 135:35-36.
Bessho K, Kusumoto K, Fujimura K. Konishi Y, Ogawa Y, Tani Y and Iizuka T. Comparison of recombinant and purified human bone morphogenetic protein. British Journal of Oral and Maxillofacial Surgery, 1999; 37:2-5.
Boström MP, Saleh KJ & Einhorn TA. Osteoinductive growth factors in preclinical fracture and long bone defects models. Orthop Clin North Am 1999; 30:647–658.
Bostrom M.P. & Camacho N.P. Potential role of bone morphogenetic proteins in fracture healing, Clin Orthop
Relat Res 1998; 355:274–282.
Bostrom MP, Lane JM, Berberian WS, Missri AA, Tomlin E, Weiland A, Doty SB, Glaser D & Rosen VM.Immunolocalization and expression of bone morphogenetic proteins 2 and 4 in fracture healing J Orthop Res
; 13:357-367.
Nakase T, Nomura S, Yoshikawa H, Hashimoto J, Hirota S, Kitamura Y, Oikawa S, Ono K and Takaoka K. Transient and localized expression of bone morphogenetic protein 4 messenger RNA during fracture healing. J Bone Miner Res
; 9:651–659.
Bax BE, Wozney JM & Ashhurst DE. Bone morphogenetic protein-2 increases the rate of callus formation after fracture of the rabbit tibia. Calcif Tissue Int 1999; 65:83–89.
Welch RD, Jones AL, Bucholz RW, Reinert CM, Tjia JS, Pierce WA, Wozney JM & Li XJ. Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J Bone Miner Res 1998; 13:1483–1490.
Shapiro F, Koide S & Glimcher MJ. Cell origin and differentiation in the repair of full-thickness defects of articular
cartilage. J Bone Joint Surg 1993; 75:532–553.
Flechtenmacher J, Huch K, Thonar EJ, Mollenhauer JA, Davies SR, Schmid TM, Puhl W, Sampath TK, Aydelotte MB & Kuettner KE. Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes. Arthritis Rheum 1996; 39:1896–1904.
Klein-Nulend J, Louwerse RT, Heyligers IC, Wuisman PI, Semeins CM, Goei SW & Burger EH. Osteogenic protein (OP-1, BMP-7) stimulates cartilage differentation of human and goat perichondrium tissue in vitro. J Biomed Mater Res 1998; 40:614–620.
Gregic M, Jelic M, Basic V, Basic N, Pecina M & Vukicevic S. Regeneration of articular cartilage defects in rabbits by osteogenic protein-1 (bone morphogenetic protein-7). Acta Med Croatica 1997; 51:23–27.
Sailor LZ, Hewick RM & Morris EA. Recombinant human bone morphogenetic protein-2 maintains the articular
chondrocyte phenotype in long-term culture. J Orthop Res 1996; 14:937–945.
Laitinen M. Osteoinductivity mediated by malignant bone tumor-derived bone morphogenetic proteins: in vivo and in vitro models. Thesis, Acta Universitatis Tamperensis 1999, 665.
Sellers RS, Zhang R, Glasson SS, Kim HD, Peluso D, D’Augusta DA, Beckwith K & Morris EA. Repair of articular
cartilage defects one year after treatment with recombiant human bone morphogenetic protein-2 (rhBMP-2). J Bone Joint Surg 2000; 82:151–160.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
